CARM · As filed with the SEC
Carisma Therapeutics balance sheet, by quarter
The statement as Carisma Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Unaudited Consolidated Balance Sheets · USD thousands
| USD thousands | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 | Q1 2024 Mar 31, 2024 | Q4 2023 Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | 2,777,000 | 1,999,000 | 7,740,000 | 17,909,000 | 26,881,000 | 40,362,000 | 56,515,000 | 77,605,000 |
| Marketable securities | — | — | — | — | — | — | — | 0 |
| Prepaid expenses and other assets | 3,090,000 | 2,285,000 | 2,901,000 | 5,916,000 | 7,256,000 | 10,359,000 | 4,438,000 | 2,866,000 |
| Assets held for sale | 3,000 | 11,000 | 3,313,000 | — | — | — | — | — |
| Total current assets | 5,870,000 | 4,295,000 | 13,954,000 | 23,825,000 | 34,137,000 | 50,721,000 | 60,953,000 | 80,471,000 |
| Property and equipment, net | 0 | 0 | 0 | 4,385,000 | 5,391,000 | 6,531,000 | 7,550,000 | 6,764,000 |
| Right of use assets - operating leases | 684,000 | 717,000 | 1,999,000 | 2,040,000 | 2,322,000 | 1,945,000 | 5,150,000 | 2,173,000 |
| Deferred financing costs | — | — | — | — | — | — | 142 | 146 |
| Deferred financing costs | 0 | 0 | 0 | 208,000 | 208,000 | 142,000 | — | — |
| Total assets | 6,554,000 | 5,012,000 | 15,953,000 | 30,458,000 | 42,058,000 | 59,339,000 | 73,795,000 | 89,554,000 |
| Liabilities and Stockholders' Deficit | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | 5,571,000 | 4,757,000 | 3,251,000 | 2,081,000 | 1,728,000 | 2,033,000 | 2,166,000 | 3,933,000 |
| Accrued expenses | 1,088,000 | 2,528,000 | 4,705,000 | 7,448,000 | 4,542,000 | 9,241,000 | 4,729,000 | 7,662,000 |
| Deferred revenue | 0 | 0 | 0 | 3,729,000 | 682,000 | 659,000 | 1,189,000 | 1,413,000 |
| Operating lease liabilities | 153,000 | 703,000 | 998,000 | 832,000 | 1,386,000 | 1,179,000 | 2,474,000 | 1,391,000 |
| Finance lease liabilities | 0 | 349,000 | 640,000 | 905,000 | 1,074,000 | 1,283,000 | 1,390,000 | 544,000 |
| Other current liabilities | 0 | 613,000 | 853,000 | 1,060,000 | 1,146,000 | 1,222,000 | 1,193,000 | 965,000 |
| Total current liabilities | 6,812,000 | 8,950,000 | 10,447,000 | 16,055,000 | 10,558,000 | 15,617,000 | 13,141,000 | 15,908,000 |
| Deferred revenue | 0 | 41,250,000 | 41,250,000 | 41,250,000 | 41,250,000 | 41,250,000 | 45,000,000 | 45,000,000 |
| Convertible promissory note | — | — | — | — | — | — | — | 0 |
| Derivative liability | — | — | — | — | — | — | — | 0 |
| Operating lease liabilities | 609,000 | 648,000 | 687,000 | 724,000 | 761,000 | 795,000 | 2,759,000 | 860,000 |
| Finance lease liabilities | 0 | 0 | 0 | 20,000 | 96,000 | 502,000 | 869,000 | 328,000 |
| Other long-term liabilities | 0 | 169,000 | 231,000 | 318,000 | 519,000 | 815,000 | 1,131,000 | 926,000 |
| Total liabilities | 7,421,000 | 51,017,000 | 52,615,000 | 58,367,000 | 53,184,000 | 58,979,000 | 62,900,000 | 63,022,000 |
| Convertible preferred stock | — | — | — | — | — | — | — | 0 |
| Stockholders' deficit: | ||||||||
| Preferred stock $0.001 par value, 5,000,000 shares authorized, none issued or outstanding | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Common stock $0.001 par value, 350,000,000 shares authorized, 41,788,096 and 41,750,109 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 41,000 | 41,000 | 41,000 | 41,000 | 41,000 | 41,000 | 41,000 | 40,000 |
| Additional paid-in capital | 278,994,000 | 278,573,000 | 278,142,000 | 277,629,000 | 276,777,000 | 275,561,000 | 274,934,000 | 271,594,000 |
| Accumulated other comprehensive loss | — | — | — | — | — | — | — | 0 |
| Accumulated deficit | (279,902,000) | (324,619,000) | (314,845,000) | (305,579,000) | (287,944,000) | (275,242,000) | (264,080,000) | (245,102,000) |
| Total Carisma Therapeutics Inc. stockholders’ equity (deficit) | — | — | — | — | — | — | — | 26,532 |
| Noncontrolling interests | — | — | — | — | — | — | — | 0 |
| Total stockholders' deficit | (867,000) | (46,005,000) | (36,662,000) | (27,909,000) | (11,126,000) | 360,000 | 10,895,000 | 26,532,000 |
| Total liabilities and stockholders' deficit | 6,554,000 | 5,012,000 | 15,953,000 | 30,458,000 | 42,058,000 | 59,339,000 | 73,795,000 | 89,554,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.